N Engl J Med 353 (16): 1673-84, 2005.[PUBMED Abstract] Perez E, Romond E, Suman V, et al.: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patiens with HER2-positive breast cancer.
[Abstract] J Clin Oncol 25 (Suppl 18): 512, 6s, 2007.
Perez EA, Romond EH, Suman VJ, et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
J Clin Oncol 32 (33): 3744-52, 2014.[PUBMED Abstract] Slamon D, Eiermann W, Robert N, et al.: Adjuvant trastuzumab in HER2-positive breast cancer.